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Abstract   
Background  Fluorine-18 sodium fluoride (NaF)- a bone-seeking radiopharmaceutical 
employed to detect osseous metastases, localizes in regions of microcalcification in 
atherosclerosis.  
Objectives To determine if atherosclerosis of penile arteries plays a role in erectile 
dysfunction (ED), we analyzed NaF images in prostate cancer patients.  
Methods (NaF) PET-CT bone scans were evaluated in 437 prostate cancer patients (age 
66.68.7 years). Their urologic histories were reviewed for Prevalent ED (diagnosed 
before the scan date), or Incident ED (no ED at first scan, but developed during 1-year 
follow-up); patients with No ED (neither before the scan nor during follow-up) were 
included as control group. A semicircular ROI was set on the dorsal half of the penis (to 
avoid residual excreted activity in the urethra) on 5 contiguous slices at the base of 
penis on PET-CT coronal reconstructions, and the average SUVmax was described as 
NaF uptake. 
Results Of 437 patients, 336 (76.9%) had Prevalent ED, 60 Incident ED (13.7%), and 
41 had No ED (9.4%). SUVmax in patients with Prevalent (median 1.88; IQR 1.67-2.16) 
or Incident (1.86; 1.72-2.08) ED was significantly higher than No ED (1.42; 1.25-1.54) 
patients (p <0.001). After adjustment for other risk factors, the Odds Ratio of Prevalent 
or Incident ED was 25.2 (95% CI: 9.5-67.0) for every 0.5 unit increment in SUVmax 
with ROC area of 0.91 (0.88-0.94).  
Conclusions NaF uptake in penile vessels is associated with ED in prostate cancer 
patients. The importance of NaF uptake needs to be tested in non-cancer subjects and 
cause-effect relationship needs to be established. 
 
Condensed Abstract To determine if atherosclerosis of penile arteries plays a role in 
erectile dysfunction (ED), we analyzed Fluorine-18 sodium fluoride (NaF) images in 
prostate cancer patients. Of 437 patients, SUVmax of penile vessels in patients with 
Prevalent (median 1.88; IQR 1.67-2.16) or Incident (1.86; IQR 1.72-2.08) ED was 
significantly higher than No ED (1.42; IQR 1.25-1.54) patients (p <0.001). After 
adjustment for other risk factors, the odds of Prevalent or Incident ED was 23.5 (95% 
CI: 9.0-61.3) for 0.5 unit increment in SUVmax with ROC area of 0.91 (95%CI: 
0.88-0.94) for ED. NaF uptake in penile vessels is associated with ED. 
Key words Atherosclerosis, Calcification, Erectile Dysfunction, NaF, Sodium Fluoride 
Abbreviations list NaF: Fluorine-18 sodium fluoride, ED: erectile dysfunction, EBRT: 
external beam radiotherapy, ROC: receptor operating characteristic, AUC: areas under 
curve 
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Introduction: 
Erectile dysfunction (ED) shares multiple risk factors with atherosclerosis (1). Previous 
studies have demonstrated the relationship of ED to increasing age, obesity, smoking, 
hypertension (HTN), metabolic syndrome, diabetes mellitus (DM) and dyslipidemia 
(2-4).  Endothelial dysfunction, which is commonly linked to all risk factors, is 
considered to play a major role in ED (5,6), and may be the precursor of early 
atherosclerotic processes. To determine if atherosclerotic involvement of penile 
vasculature contributes to ED, we analyzed Fluorine-18 sodium fluoride (NaF) PET-CT 
images in prostate cancer patients. NaF, which is a bone-seeking radiopharmaceutical 
and is used to detect osseous metastases, is also known to localize in the focal areas of 
active microcalcification in atheromatous plaques (7-10).  
We hypothesized that NaF uptake in penile vessels could serve as a marker of 
vasculogenic ED. We had, during our review of bone scans, frequently noted NaF 
uptake in penile arteries which led to the current hypothesis. The present study 
investigates the relationship of penile vascular NaF uptake in patients with and without 
ED. 
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Methods: 
Study population 
The institutional review board approved this retrospective study and waived the 
necessity for a written informed consent. Prostate cancer patients (n= 442) who had NaF 
bone scans for detection of osseous metastases were enrolled in this study. The urologic 
histories were reviewed to determine the presence of ED at the time of initial and 1-year 
follow-up scans. ED was present when a diagnosis had been established by an 
experienced urologist or the International Index of Erectile Function (IIEF-5) score was 
<21 in the absence of any drugs known to cause ED. Five patients with penile implants 
were excluded from analysis reducing the study cohort to 437 patients. Patients were 
divided into 3 groups; (I) Prevalent ED, i.e. ED diagnosed before the date of scan, (II) 
Incident ED, i.e. no ED at the time of the first scan, but ED developed during 1-year 
follow-up, (III) No ED, i.e. ED neither at the first date nor during follow-up; this group 
was treated as the control group. Coronary risk factors on the scan dates were also 
obtained.  
  
PET-CT Protocols and Image Reconstruction 
Approximately 70 min after intravenous injection of 5-6 mCi 
18
F-NaF, whole body 
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PET-CT images were acquired on integrated PET-CT systems (Discovery 690 or 710; 
GE Healthcare, Milwaukee, USA). A low dose CT (120 kVp, 40-100 mA based on the 
body weight, 0.8 second per rotation, and 3.75mm slice thickness) was performed for 
attenuation correction and anatomic registration. No iodinated contrast material was 
administered. PET images were acquired from the vertex to the feet in 3-dimensional 
mode for 3 minutes per bed position. PET-CT images were transferred to an offline 
workstation and reconstructed into coronal, axial and sagittal planes with dedicated 
software (Hermes hybrid viewer software; Hermes Medical Solutions, Stockholm, 
Sweden).    
To evaluate NaF uptake in penile arteries at the base of the penis five consecutive 
coronal PET-CT images and the corresponding CT were analyzed. The first slice was at 
the anterior-inferior margin of the symphysis pubis, and incremented anteriorly by one 
PET slice (with corresponding CT) for each of the remaining 4 slices. The images were 
evaluated for both calcifications on CT and fluoride PET uptake in the dorsal artery and 
cavernosal vessels (PET). To exclude residual excreted activity in urine within the 
penile urethra, a semi-circle ROI was set on the upper half of the penis (Central 
Illustration A, B, C, D). The average SUV max(11) of 5 ROIs was defined as the NaF 
uptake. The comparable slices on CT were evaluated for CT calcification (>130 
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Hounsfield units) using an OsiriX workstation (Osirix version 32 bit; OsiriX Imaging 
Software, Geneva, Switzeland). This software was also used to measure CT 
calcification in the common carotid (CCA) and common/internal iliac (CIA/IIA) arteries. 
For measurement of coronary calcification, we used the 0-12 scoring method developed 
for non-gated scans (12,13). 
 
Statistical Analysis  
Intraobserver and interobserer variability in NaF measurements was assessed using 
Bland-Altman analysis and Spearman’s rank correlation coefficients.  Data are 
presented as median (interquartile range, IQR; i.e. 25th to 75th percentile, or Q1, Q3) or 
as Mean1SD. Continuous data were compared using Mann-Whitney U test between 2 
the groups or Kruskal-Wallis test with post ad -hoc Dwass, Steel, Critchlow-Fligner 
(DSCF) multiple comparison analysis. Proportions were compared with Fisher’s exact 
probability test. We examined differences in SUVmax in various groups including in 
patients with extra-capsular extension of their prostate cancer or evidence of neuronal 
involvement of histopathology (See below). The Spearman Rank Correction coefficient 
test was used for the assessment of linear correlation of two parameters. We used 
multivariable logistic regression model to study the relationship between ED and NaF 
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SUVmax after adjusting for potential confounders. The areas under curve (AUC) of 
receptor operating characteristic (ROC) curve were used to compare incremental 
diagnostic utility of NaF for diagnosis of Prevalent ED or Incident ED. A two-sided p 
<0.05 was considered statistically significant. Statistical analyses were performed with 
SAS software, version 9.4., SAS Institute Inc., Cary, NC, USA. 
 
 
Results  
Patient characteristics 
Of the 437 patients with prostate cancer (age 66.68.7 years, BMI 28.94.4), 244 
patients had hypertension (HTN, 56%), 247 dyslipidemia (57%), 70 type 2 diabetes 
mellitus (DM, 16%), and 204 reported a smoking history (47%; 26 currently smokers); 
52 (12%) patients had a history of coronary artery disease (Table 1). Based on 
histopathology, ED patients with (n=165) or without (n=31) extracapsular extension of 
prostate cancer and with (n=173) or without (n=7) evidence of neuronal involvement 
were also separately evaluated and compared with no ED group. As presented in Figure 
1, 220 patients had radical prostatectomy prior to the NaF scan (4.14.4 years) and 45 
patients had radical prostatectomy within one year after the (NaF) PET-CT. 145 patients 
8 
 
were treated with radiation (25 seed implant and 131 external beam radiotherapy 
(EBRT)); interval from initial EBRT to NaF scan was 7.75.0 years, salvage EBRT to 
NaF scan was 4.63.7 years, brachytherapy to NaF scan was 8.14.1 years, and total 
6.24.6 years. 139 patients received androgen deprivation therapy (ADT) with or 
without other radiation therapy and surgical intervention within 6 months. Finally, 92 
patients were monitored for follow-up without any active surgical, radiation or 
hormonal therapy.  
 
NaF uptake and ED 
Penile NaF uptake was commonly observed in the ED patients (Figure 2); the uptake 
was observed distinctly from the urethral activity in the cavernous and dorsal penile 
arteries. Former vessels are considered important for cavernous filling and erectile 
competence. Quantitative penile NaF uptake in Prevalent ED (SUVmax1.88; IQR 
1.67-2.16) and Incident ED (SUVmax 1.86; IQR 1.72-2.08) was significantly higher than 
in No ED (SUVmax 1.42; IQR 1.25-1.54) patients (p<0.001) (Figure 3). Quantification 
of penile NaF uptake demonstrated excellent inter- and intra- observer reproducibility 
(Supplemental Figure 1). The age adjusted mean difference in SUVmax was higher by 
0.53 (0.37-0.60) among Prevalent ED and by 0.56 (0.44-0.61) among Incident ED 
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patients compared to No ED. In our study cohort, IIEF scores were available for 176 
patients at baseline and 1-year follow-up IIEF score for 90 patients. NaF uptake was 
negatively correlated with IIEF score (R =-0.26, p <0.001, n = 144 Prevalent ED, 13 No 
ED) at baseline and at 1-year follow-up (R =-0.32, p <0.001, n = 69 Prevalent ED, 11 
Incident ED, 10 No ED patients). On the other hand, even though higher, there was no 
statistically significant difference in CT-verified calcium score in the carotid, internal 
iliac, common iliac and penile arteries among Prevalent and Incident ED compared with 
No ED. In the coronary arteries (on the ungated scale of 0-12 score), the calcium score 
showed significant difference in three groups, it was higher in Prevalent ED patients 
than in No ED patients albeit statistically non-significant (p=0.07) in multiple 
comparisons (Table 1). Penile NaF uptake was not significantly different in ED patients 
with [1.86 (1.64-2.10); n=165] or without extracapsular extension [1.83 (1.61-2.01); 
n=31], nor in ED patients with [183 (1.63–2.10); n=173] or without perineural invasion 
[1.91 (1.66–2.29); n=7]. 
Although Prevalent ED patients were older (67.58.3 years) than No ED (64.09.4 
years) or Incident ED (63.59.6 years), there was only a modest correlation between age 
and SUV max (R =0.22, p <0.001). The BMI was not significantly different between No 
ED (28.13.8 kg/m2), Incident ED (29.45.0 kg/m2), and Prevalent ED (29.04.3 
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kg/m
2
) groups but showed a significant correlation with the SUVmax (R =0.37, p <0.001). 
The eGFR (MDRD) was not significantly different between the No-ED (84.423.9 
ml/min/1.73m
2
), Incident ED (85.219.4 ml/min/1.73m2), and Prevalent ED (82.920.5 
ml/min/1.73m
2
) and showed no correlation with the SUVmax (R =-0.08, p =0.12) (Table 
1). SUVmax was significantly higher in patients with hypertension, diabetes and prior 
radiation therapy. SUVmax was not different in patients with a history of smoking, CAD 
and/or radical prostatectomy. Dyslipidemia did not affect SUVmax and, in the subgroup 
with dyslipidemia, statin did not affect SUVmax (Supplemental Table 1).  
After adjustment for age, BMI, eGFR, hypertension, hyperlipidemia, diabetes mellitus, 
smoking status, prevalent CAD, prior radiation therapy, prior prostate surgery and ADT, 
the Odds Ratio of any ED (Prevalent or Incident versus NO ED) was 25.2 (95% C.I.: 
9.5–67.0) for each 0.5 unit increment in SUVmax (Supplemental Table 2). Only a 
negligible change occurred after adding all other clinical variables, including CT 
calcification in the coronary, carotid, common/internal iliac arteries, and penile arteries 
to this model. The strong relationship between SUVmax and ED was also reflected in 
area under ROC of 0.91 (95% C.I.: 0.88 –0.94) in a model with SUVmax alone as 
predictor (Figure 4). 
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Effect of therapeutic strategy on NaF uptake  
Because ED may also result as a consequence of the treatment, such as nerve injury, we 
reviewed the results separately in groups of patients treated by surgical, radiation or 
hormonal protocols (14). In all subgroups SUVmax was higher for the Prevalent and 
Incident ED including only radiation [2.01 (1.83–2.40); n =36], only prostatectomy 
[1.81 (1.59–2.10); n =111], only androgen deprivation therapy [1.94 (1.69–2.16); n=40] 
and those only under surveillance without any surgical, radiation or hormonal 
intervention[1.84 (1.63–2.16); n =79] compared to the No ED patients (p <0.05) (Figure 
3). Within one year after the (NaF) PET-CT, 45 patients underwent radical 
prostatectomy, 46 patients received radiation therapy and 153 patients were treated with 
ADT. However, these therapies within one year after the NaF imaging did not influence 
Incident ED. Although medications, especially beta-blockers and anxiolytics, and 
anti-depressant agents including selective serotonin-inhibitors, which could potentially 
cause ED did not influence the Prevalent or Incident ED (p NS) (Supplemental table 3). 
 
 
 
Discussion 
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NaF Imaging in Erectile Dysfunction 
This study showed that penile NaF uptake was associated with the presence of ED and 
the likelihood of future ED. It is possible that penile NaF uptake is an indicator of penile 
vascular pathology and hence vasculogenic ED. Using SUVmax of 1.56 as the cut-off 
value based on the ROC analysis, NaF uptake showed sensitivity of 85%, specificity 
80%, positive predictive value of 98% and negative predictive value 35%, with 
diagnostic accuracy of 84%. The low negative predictive value is due in part to the 
small number of No ED patients or could represent the patients with non-vasculogenic 
ED, such as that could result from psychologic, neurologic, or hormonal causes (1-3,14). 
A sub-analysis of MESA study showed coronary calcium score to be an important 
predictor of endothelial and erectile dysfunction (15). Although our study population 
was smaller (n= 437, CAD 52) compared to 1862 men (age 45-84 years, free of CAD) 
in the MESA study, our results of calcium scores were compatible with the MESA study. 
The ROC analysis and Odds Ratio showed NaF ED was superior to coronary calcium 
score to predict ED.   
 
Pathogenetic basis of NaF uptake in Erectile Dysfunction 
NaF has been used for more than 50 years (16) as a tracer to detect osseous metastasis. 
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It has also been proposed that NaF uptake could identify the active process of 
microcalicifiaction in atheromatous plaques (7,17,18). The initial step of 
microcalcification in atheroma involves extracellular vesicles, including matrix vesicles 
and apoptotic bodies in the necrotic core (19), which serve as nucleation sites for 
calcium phosphate deposition. As microcalcification increases, it coalesces into large 
masses or triggers a calcification cascade (as seen in bone formation) and results in 
macrocalcification (10,20).  
There are no reports describing the use of NaF to evaluate possible atherosclereosis in 
erectile dysfunction. The artery size hypothesis, suggests that a relatively small decrease 
in penile aretery diameter, such as due to plaque, could cause ED (21). In an autopsy 
study of 31 subjects, the prevalence of atherosclerotic lesions in penile arteries (12.9%) 
was lower that of the coronary arteries (87.1%) and internal iliac arteries (77.4%) (22).  
AHA type Vb atherosclerosis was observed in penile arteries, wherein the mineral 
deposition is expected to have replaced the contents of the atheromatous necrotic core. 
From these observations, it is conceivable that NaF should localize in early 
microcalcific foci in penile vessels. The fluoride uptake provides information that 
differs from late calcification seen on CT (10).  
Due to the limited spatial resolution (3-5mm) of PET imaging, it is not certain if the 
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penile NaF uptake is localized to cavenous arteries. Since there was no significant 
correlation between iliac calcification and penile fluoride uptake, it is also possible that 
calcification could be associated with the venous compartment or smooth muscle cell 
damage leading to possible venous insufficiency and ED.  
 
Inflammation as the basis of vascular involvement and NaF uptake 
Inflammation, which is the obligatory component of atherosclerosis, has been proposed 
as the precursor of microcalcification and NaF uptake (10). Although nerve injury from 
prostatectomy has been widely implicated as an etiology of ED, Mulhall and colleagues 
have emphasized that ED is associated with arterial insufficiency and venous leakage 
especially when the cavernous nerve remained unaffected during radical prostatectomy 
(23). The result of the current study with high prevalence of NaF uptake in the penile 
vasculature in ED patients is consistent with their data. Further, the relationship between 
ED and external beam radiation was reported in the 1970s, with impotence occurring 
several months to several years after therapy (24,25), possibly an inflammatory 
consequence of irradiation. Our study demonstrated that patients who received radiation 
therapy more than 3 years before NaF scan showed a high odds ratio in univariate 
analysis [Odds Ratio: 12.3 (95%CI: 1.7-90.5)], but did not achieve statistical 
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significance in multivariable analysis (Supplemental Table 2). It is possible that vascular 
risk factors act synergistically with radiation to result in ED (25). Animal studies have 
demonstrated that radiation induced inflammation could accelerate development of 
atherosclerotic lesions in ApoE
-/-
 mice (26,27).  
 
To evaluate if inflammation was a necessary accompaniment of NaF uptake in ED 
patients, we reviewed a subset of 63 patients who had undergone both (FDG) PET-CT 
and (NaF) PET-CT scans within 6 months of each other (Supplemental Figure 2); FDG 
uptake is an established marker of vascular inflammation. There was, however, no 
significant difference of penile FDG uptake in the No ED [1.52 (1.09-2.29); n= 7], 
Incident ED [1.64 (1.33-2.07); n= 11], or Prevalent ED [1.95 (1.63-2.40); n= 45] groups 
(p= 0.08). Also, there was no significant correlation between NaF uptake and FDG 
uptake (r=0.15, p=0.24). However, SUVmax of FDG was significantly higher in patients 
treated with irradiation [2.29 (1.85-2.42); n=19] compared to those without radiation 
therapy [1.77 (1.51-2.05); n=44, p<0.05]; NaF imaging also demonstrated a trend (albeit 
statistically insignificantly) towards higher uptake in the radiation group supporting an 
inflammatory basis. In all other patients, ED correlated with increased penile fluoride 
uptake, but not with FDG uptake, suggesting that the calcification may not necessarily 
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be associated with the inflammatory stage of the atherosclerotic process. Medial and 
intimal calcification is commonly seen in peripheral artery disease regardless of 
inflammation (28), and may also contribute to penile NaF uptake.  
 
Management strategy, ED and NaF uptake 
In our series of unselected prostatic malignancy patients, variable degrees of Prevalent 
ED were reported in 77% of patients, which might seem high. A plausible approach to 
evaluate the true prevalence of ED in the prostate cancer patients is to compare No ED 
patients with Incident ED patients, because all patients in these 2 groups should not 
have erectile dysfunction at the time of initial scan, the Incident ED patients developed 
erectile dysfunction during follow up. Whereas 41 patients belonged to No ED group, 
60 patients had Incident ED; approximately 60% of patients with no evidence of ED at 
baseline developed ED within the ensuing year. The impotency rates have been reported 
to range from 54-90% in the 12 months of follow up after radical prostatectomy with or 
without robot-assistance (29) and approximately 50% of patients at 5 years after 
radiation theraphy (30). The prevalence of ED in a normal population (mean age :62.3 
years old) has been reported as 52% (31). Considering our patients were older than 66 
years, the prevalence of ED in our study is not an overestimate. In the subgroup of No 
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ED vs Incident ED (n=101) patients, ROC curve analysis showed a high diagonstic 
accuracy of NaF SUVmax for Incident ED, with the area under the curve of 0.91 
(95%CI: 0.86-0.97) (Supplemental Figure 3) . 
 
 
Limitations of the study.  
Although the results are intriguing and provocative, there are several limitations of this 
study. It is a retrospective study of prostate cancer patients from a single tertiary care 
referral center and the inherent bias of inclusion of only severe and complicated cases 
cannot be excluded. In addition, the number of No ED patients is small. However; 
considering published rates of ED in patients with prostate cancer as discussed above, it 
appears that we have sampled a representative group of patients with a high prevalence 
of ED. Regardless, the lower number of No ED patients reduces the confidence in our 
findings. Unfortunately, most of our patients did not have lipid profiles, so we could not 
calculate Framingham Risk Scores to evaluate relationship between risk factors and 
possible penile artey atherosclerosis. Therefore, this study still leaves open the 
possibility that the NaF uptake is a consequence of or a co-occurrence from ED causing 
mechanisms i.e. risk factors and endothelial dysfunction rather than a causative etiology 
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of ED. Finally, even though there is a higher likelihood of active penile arterial 
calcification in erectile dysfunction, the study does not prove causality nor reveals clues 
that may help manage Prevalent ED or prevent occurrence of Incident ED. 
 
Conclusions. 
Fluoride uptake in penile vessels is significantly higher in patients with Prevalent or 
Incident ED. NaF uptake occurs both in patients undergoing surgical or radiation 
therapy. The study only demonstrates a correlation and causative association needs to be 
established. Therefore, future studies would examine the role of penile vascular fluoride 
uptake as a contributor to ED especially in a general patient population. 
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Clinical Perspectives 
Altough the association of NaF uptake with ED is very strong, it is reasonable to accept 
that the NaF uptake will not influence clinical management in a significant way. 
However, this study suggests that vascular abnormality may be a more important 
mechanism of ED regardless of the management strategy.   
 
Clinical Competencies 
The study refutes the higher likelihood of ED in patients undergoing prostatectomy 
and relative sparing of ED in irradiated cancer patients. Even though not much 
preventive practice can be proposed, higher uptake of NaF is a forewarning of ED.  
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Translational Outlook 1 
Lack of relationship of penile NaF uptake with atherosclerosis in other arterial beds, 
standard coronary risk factors, and preceeding inflammation prompts us to explore other 
mechanisms and solutions of vascular impairment.  
 
Translational Outlook 2 
This study also paves the way for a systematic prospective study of NaF imaging in 
general, non cancer patients to explore underlying causes of ED.  
 
21 
 
Reference 
1. Gandaglia G, Briganti A, Jackson G et al. A systematic review of the association 
between erectile dysfunction and cardiovascular disease. European urology 
2014;65:968-78. 
2. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk 
factors: prospective results from the Massachusetts male aging study. Preventive 
medicine 2000;30:328-38. 
3. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict 
erectile dysfunction 25 years later: the Rancho Bernardo Study. Journal of the 
American College of Cardiology 2004;43:1405-11. 
4. Keenan HA. Do erectile dysfunction and cardiovascular disease have the same 
mechanism? European urology 2014;65:979-80. 
5. Castela A, Costa C. Molecular mechanisms associated with diabetic 
endothelial-erectile dysfunction. Nature reviews Urology 2016;13:266-74. 
6. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired 
brachial artery endothelium-dependent and -independent vasodilation in men with 
erectile dysfunction and no other clinical cardiovascular disease. Journal of the 
American College of Cardiology 2004;43:179-84. 
22 
 
7. Derlin T, Richter U, Bannas P et al. Feasibility of 18F-sodium fluoride PET/CT for 
imaging of atherosclerotic plaque. Journal of nuclear medicine : official publication, 
Society of Nuclear Medicine 2010;51:862-5. 
8. Fiz F, Morbelli S, Piccardo A et al. (1)(8)F-NaF Uptake by Atherosclerotic Plaque on 
PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral 
Metabolic Activity. Journal of nuclear medicine : official publication, Society of 
Nuclear Medicine 2015;56:1019-23. 
9. Irkle A, Vesey AT, Lewis DY et al. Identifying active vascular microcalcification by 
(18)F-sodium fluoride positron emission tomography. Nature communications 
2015;6:7495. 
10. Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary 
Artery Calcification: From Mechanism to Molecular Imaging. JACC Cardiovascular 
imaging 2017;10:582-593. 
11. Weber WA. Quantitative analysis of PET studies. Radiotherapy and oncology : 
journal of the European Society for Therapeutic Radiology and Oncology 
2010;96:308-10. 
12. Yankelevitz DF, Henschke CI, Yip R et al. Second-hand tobacco smoke in never 
smokers is a significant risk factor for coronary artery calcification. JACC 
23 
 
Cardiovascular imaging 2013;6:651-7. 
13. Chiles C, Duan F, Gladish GW et al. Association of Coronary Artery Calcification 
and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring 
Methods. Radiology 2015;276:82-90. 
14. Lue TF. Erectile dysfunction. The New England journal of medicine 
2000;342:1802-13. 
15. Feldman DI, Cainzos-Achirica M, Billups KL et al. Subclinical Vascular Disease and 
Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA). 
Clinical cardiology 2016;39:291-8. 
16. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. 
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 
1962;3:332-4. 
17. Dweck MR, Chow MW, Joshi NV et al. Coronary arterial 18F-sodium fluoride 
uptake: a novel marker of plaque biology. Journal of the American College of 
Cardiology 2012;59:1539-48. 
18. Joshi NV, Vesey AT, Williams MC et al. 18F-fluoride positron emission tomography 
for identification of ruptured and high-risk coronary atherosclerotic plaques: a 
prospective clinical trial. Lancet (London, England) 2014;383:705-13. 
24 
 
19. New SE, Goettsch C, Aikawa M et al. Macrophage-derived matrix vesicles: an 
alternative novel mechanism for microcalcification in atherosclerotic plaques. 
Circulation research 2013;113:72-7. 
20. Nakahara T, Strauss HW. From inflammation to calcification in atherosclerosis. 
European journal of nuclear medicine and molecular imaging 2017;44:858-860. 
21. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the "tip of the iceberg" 
of a systemic vascular disorder? European urology 2003;44:352-4. 
22. Ponholzer A, Stopfer J, Bayer G et al. Is penile atherosclerosis the link between 
erectile dysfunction and cardiovascular risk? An autopsy study. International 
journal of impotence research 2012;24:137-40. 
23. Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy--myth or 
reality? The Journal of urology 2008;179:827-31. 
24. Rhamy RK, Wilson SK, Caldwell WL. Biopsy-proved tumor following definitive 
irradiation for resectable carcinoma of the prostate. The Journal of urology 
1972;107:627-30. 
25. Goldstein I, Feldman MI, Deckers PJ, Babayan RK, Krane RJ. Radiation-associated 
impotence. A clinical study of its mechanism. Jama 1984;251:903-10. 
26. Stewart FA, Heeneman S, Te Poele J et al. Ionizing radiation accelerates the 
25 
 
development of atherosclerotic lesions in ApoE-/- mice and predisposes to an 
inflammatory plaque phenotype prone to hemorrhage. The American journal of 
pathology 2006;168:649-58. 
27. Hoving S, Heeneman S, Gijbels MJ et al. Single-dose and fractionated irradiation 
promote initiation and progression of atherosclerosis and induce an inflammatory 
plaque phenotype in ApoE(-/-) mice. International journal of radiation oncology, 
biology, physics 2008;71:848-57. 
28. O'Neill WC, Han KH, Schneider TM, Hennigar RA. Prevalence of nonatheromatous 
lesions in peripheral arterial disease. Arteriosclerosis, thrombosis, and vascular 
biology 2015;35:439-47. 
29. Ficarra V, Novara G, Ahlering TE et al. Systematic review and meta-analysis of 
studies reporting potency rates after robot-assisted radical prostatectomy. European 
urology 2012;62:418-30. 
30. Gaither TW, Awad MA, Osterberg EC et al. The Natural History of Erectile 
Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. 
The journal of sexual medicine 2017;14:1071-1078. 
31. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence 
and its medical and psychosocial correlates: results of the Massachusetts Male 
26 
 
Aging Study. The Journal of urology 1994;151:54-61. 
 
 
27 
 
Figure legends   
 
Central Illustration: The assessment of penile NaF uptake, definition of ROI, and 
calculation of SUVmax. 
(A) Schematic presentation of origin of penile arteries from common iliac, internal iliac 
and internal pudendal arteries. (B) Schematic representation of the distribution of penile 
arteries in coronal images. Main arteries (dorsal penile arteries and cavernous arteries in 
red) are located in the upper half of the penis. A semi-circle ROI is set on the upper half 
of the penis, red dots on panel B far right, avoiding urethra. Blue vessels correspond to 
veins and yellow circles correspond to the nerves. (C) (NaF) PET-CT coronal image of 
the penis (SUV Upper level is set as 2.8). High uptake is observed in the cavernous area. 
The NaF in the bottom half of the penile cross-section corresponds to the urethra. (D) 
Semi-circle ROI is set on 5 contiguous slices on PET images near the inferior margin of 
the symphysis pubis on PET-CT image (red arrows). The average of SUV max on the 5 
ROI was presented as the NaF uptake. 
 
Figure 1: Prostate cancer patients included in the present study grouped by various 
therapeutic interventions. 
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Prostate cancer patients (n= 442) who had NaF bone scans for detection of osseous 
metastases were enrolled in this study. Five patients with penile implants were excluded 
from analysis reducing the study cohort to 437 patients. Patients were treated with 
radical prostatectomy, radiation and/or androgen deprivation therapy (ADT). 
Ninety-two patients were monitored for follow-up without any active surgical, radiation 
or hormonal therapy (Active Surveillance).  
 
Figure 2: Representative (NaF) PET-CT images in Prevalent ED and No ED. 
(A) 55 year- old patient with Prevalent ED shows high NaF uptake (SUVmax 1.61) is 
observed in the area of the penile arteries (arrows). (B) 51 years old patient with No ED 
shows no evidence of NaF uptake (SUVmax: 1.21) (arrows). SUV upper level is set as 
2.0 for both scans.  
 
Figure 3: NaF uptake in Prevalent, Incident and No ED patients by therapeutic 
intervention strategy.  
NaF uptake in Prevalent and Incident ED patients is significantly higher than No ED 
patients, regardless of radiation (n=36), prostatectomy (n=111), androgen deprivation 
therapy (ADT, n=40) or surveillance (n=79) strategy. A trend of higher uptake in 
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irradiated patients is not statistically significant. 
 
Figure 4: ROC analysis to diagnose Prevalence ED or Incident ED. 
ROC analysis showed that SUVmax showed high diagnostic accuracy for Incident ED or 
Prevalent ED, with the area under ROC curve of NaF being 0.91 (95% C.I.: 0.88-0.94). 
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Table 1: Patient characteristics 
 
   No ED    Incident ED      Prevalent ED  P value 
N         41             60               336                
Age      64.0 9.4       63.59.6       67.5 8.3‡   0.001† 
BMI      28.13.8          29.45.0       29.04.3    0.754 
eGFR (MDRD)  84.4 23.9     85.219.4       82.920.5   0.601 
Hypertension  23 (56%)     29 (48%)       192 (57%)   0.450 
Dyslipidemia  18 (44%)     36 (60%)       193 (57%)   0.158 
Diabetes Mellitus  3 ( 7%)      8 (13%)       59 (18%)   0.200 
CAD       2 ( 5%)        4 ( 7%)   46 (14%)   0.105 
Smoking   15 (37%)     22 (37%)       167 (50%)   0.070 
Surgery   10 (24%)      15(25%)        195 (58%)  <0.001
†
 
Radiation   8 (20%)       7(12%)       130 (39%)  < 0.001
†
             
     EBRT    8           7   116    
     Brachy    0          0       25 
ADT   18 (44%)       16 (27%)       105 (31%)    0.171    
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NaF SuVmax  1.42 (1.25-1.54)
 
  1.86 (1.72-2.08) 
§
    1.88(1.67-2.16) 
§
  <0.001 
†
  
Ca 12 score     2.0 (0.0-3.0)      2.0 (0.0-4.0)        2.5 (1.0-5.0)     0.042* 
CCA CS        0.0 (0.0-17.5)     5.0 (0.0-82.0)       5.0 (0.0-84.0)   0.131 
CIA CS     165.0 (28.0-834.0)  228.5 (16.3-731.3)   338.5 (26.3-1374.3)   0.260 
IIA CS        40.0 (12.0-247.0)   92.0 (18.8-342.5)  133.0 (18.0-471.8)    0.135 
PA CS        18.0 (2.0-36.0)     13.0 (0.0-42.8)       9.0 (0.0-27.0)   0.137  
                                                                                            
 
BMI: Body Mass Index, CAD: Coronary Artery Disease, EBRT: External Beam 
Radiation Therapy, ADT: Androgen Deprivation Therapy, , Ca 12 score: Coronary 
artery calcification 12 score, CCA CS: Common Carotid Artery Calcium Score, CIA 
CS: Common Iliac Artery Calcium Score: CIA, IIA CS: Internal Iliac Artery Calcium 
Score, PA CS: Penile artery Calcium Score. 
*: P<0.05, †: P<0.01 from Kruskal-Wallis’s test for 3 groups.  
With post ad –hoc Dwass, Steel, Critchlow-Fligner (DSCF) multiple comparison 
analysis, ‡ Age was higher in Prevalent ED group as compared to Incident ED and No 
ED group. § NaF was higher in Incident ED and Prevalent ED group as compared to the 
No ED group. Ca 12 score showed significant difference in Kruskal-Wallis’s test, 
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however; it do not showed the difference in DSCF analysis. 
 
 





